Key Insights from ViVE and HIMSS 2026

Key Insights from ViVE and HIMSS 2026
Key Insights from ViVE and HIMSS 2026
David Schummers
LinkedIn Logo
Chief Executive Officer
March 24, 2026

ViVE and HIMSS were incredible this year. The energy and excitement around AI tools were at the highest levels I’ve seen at these conferences over the past three or four years.

That excitement is being driven by the successful transition of AI technologies from pilot programs to enterprise-scale deployments. This shift — from experimenting with new tools to fully deploying them across health systems — was one of the most prominent themes at both conferences.

One of the most exciting areas of innovation right now is the agentification of workflows in hospitals. A clear theme at both ViVE and HIMSS was that agents are arriving — and they’re actively being deployed across healthcare workflows.

Learn how hospitals using Apella added an average 2 cases per OR per month.
Read the full analysis

What AI agents need most to achieve their promise of healthcare transformation

What makes this particularly exciting is that agents perform best when they are built on high-quality data. The solutions that will enable agents to succeed are those that provide reliable, structured data — data that is meaningfully better than what currently exists in healthcare systems of record.

Today, systems of record in the clinical domain are quite strong. However, systems of record in the operational and workflow domains still need significant improvement, particularly in transforming unstructured data into structured, usable formats. The organizations that succeed will be those that can deliver high-quality data as a foundational layer.

How to discern if an AI model for healthcare is ready for enterprise scale 

For Apella, one of the accomplishments I’m most proud of over the past few months is our first peer-reviewed publication. In it, we describe the technical capabilities of our system, including our artificial intelligence and computer vision models.

The publication demonstrates that our models achieve best-in-class F1 scores. If we’re going to build trusted systems in healthcare, it will be on the back of this kind of high-quality, reliable data — data that we’ve not only developed and deployed, but also rigorously validated and published.

Learn how hospitals using Apella added an average 2 cases per OR per month.
Read the full analysis
Key Insights from ViVE and HIMSS 2026

David is a co-founder and the chief executive officer of Apella. David started his healthcare career over 20 years ago in finance, covering emerging medical technology companies and large diversified healthcare companiies. Through this experience, he was drawn to the entrepreneur energy and decided to transition to operating companies focused on new technologies. David has been on leadership teams that created new standards of care for multiple disease states including spinal pathologies, gastrointestinal disorders and cancers. Most recently, David joined Auris Health in 2014 as the company's first commercial executive and helped transition the company from an early start up to the largest start-up transaction in medical technology history, a $5.7B sale to Johnson and Johnson in 2019.